Victory Capital Management Inc. boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,741,654 shares of the biopharmaceutical company’s stock after buying an additional 135,615 shares during the period. Victory Capital Management Inc. owned approximately 1.98% of Amicus Therapeutics worth $45,237,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of FOLD. BlackRock Inc. grew its position in Amicus Therapeutics by 6.1% in the 2nd quarter. BlackRock Inc. now owns 16,017,301 shares of the biopharmaceutical company’s stock valued at $250,190,000 after acquiring an additional 927,049 shares in the last quarter. Morgan Stanley grew its position in Amicus Therapeutics by 519.6% in the 2nd quarter. Morgan Stanley now owns 4,968,627 shares of the biopharmaceutical company’s stock valued at $77,610,000 after acquiring an additional 4,166,756 shares in the last quarter. Northern Trust Corp grew its position in Amicus Therapeutics by 9.3% in the 2nd quarter. Northern Trust Corp now owns 2,394,490 shares of the biopharmaceutical company’s stock valued at $37,401,000 after acquiring an additional 203,444 shares in the last quarter. Bank of New York Mellon Corp grew its position in Amicus Therapeutics by 0.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,046,768 shares of the biopharmaceutical company’s stock valued at $31,970,000 after acquiring an additional 6,931 shares in the last quarter. Finally, Novo Holdings A S acquired a new position in Amicus Therapeutics in the 2nd quarter valued at about $16,888,000.
In related news, major shareholder Perceptive Advisors Llc acquired 20,000 shares of the stock in a transaction dated Monday, September 24th. The stock was acquired at an average cost of $12.45 per share, with a total value of $249,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $12.23, for a total value of $122,300.00. Following the transaction, the chief financial officer now directly owns 127,622 shares of the company’s stock, valued at $1,560,817.06. The disclosure for this sale can be found here. Over the last three months, insiders have bought 620,000 shares of company stock valued at $7,505,000. Corporate insiders own 2.90% of the company’s stock.
Several equities analysts have weighed in on FOLD shares. Chardan Capital reaffirmed a “hold” rating and issued a $15.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 12th. BidaskClub downgraded Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Finally, Citigroup started coverage on Amicus Therapeutics in a research report on Monday, October 29th. They issued a “neutral” rating and a $12.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $19.50.
Shares of Amicus Therapeutics stock opened at $10.59 on Friday. Amicus Therapeutics, Inc. has a one year low of $10.33 and a one year high of $17.62. The company has a quick ratio of 10.73, a current ratio of 9.12 and a debt-to-equity ratio of 0.78.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. The company had revenue of $20.60 million for the quarter, compared to analyst estimates of $23.56 million. During the same period in the prior year, the firm posted ($0.41) earnings per share. The business’s quarterly revenue was up 89.0% compared to the same quarter last year. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Featured Article: Conference Calls and Individual Investors
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.